Highlights Newsletter 2
This newsletter presents you the following key sessions:
1. Video interview with dr. Jordan Schaefer about the impact of adding aspirin to direct anticoagulant therapy without
an apparent indication
2. The anti-CD19 CAR construct lisocabtagene maraleucel induces a rapid, high rate of durable responses in patients
with relapsed/refractory large B-cell lymphoma
3. Sustained progression-free and overall survival benefit of time-limited venetoclax-rituximab over bendamustine-
rituximab in relapsed/refractory CLL
4. Older myeloma patients can safely undergo an autologous stem cell transplantation and achieve similar benefits
as younger patients
5. Significant reduction in severe graft-versus-host disease with post-transplantation cyclophosphamide after
allogeneic hematopoietic stem cell transplantation